The impact of carcinoembryonic antigen flare in patients with advanced colorectal cancer receiving first-line chemotherapy

Annals of Oncology

Volumn 21, Issue 5, 2009, Pages 1013-1019

  Strimpakos, A S ^a   Cunningham, D ^a   Mikropoulos, C ^a   Petkar, I ^a   Barbachano, Y ^a   Chau, I ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

Carcinoembryonic antigen; Chemotherapy; Colorectal cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARCINOEMBRYONIC ANTIGEN; FLUOROPYRIMIDINE DERIVATIVE; IRINOTECAN; OXALIPLATIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER SURVIVAL; COLORECTAL CANCER; CONTROLLED STUDY; DRUG RESPONSE; FEMALE; HIGH RISK PATIENT; HUMAN; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARCINOEMBRYONIC ANTIGEN; COLORECTAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; ORGANOPLATINUM COMPOUNDS; PROGNOSIS; SURVIVAL RATE; YOUNG ADULT;

EID: 77953350910     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp449     Document Type: Article

References (18)

1. Ferlay J, Bray F, Pisani P et al. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide, IARC CancerBase No. 5 Version 2.0. Lyon: IARC Press 2004.
2. Benchimol S, Fuks A, Jothy S et al. Carcinoembryonic antigen, a human tumor marker, functions as an intercellular adhesion molecule. Cell 1989; 57: 327-334.
3. Goldstein MJ, Mitchell EP. Carcinoembryonic antigen in the staging and followup of patients with colorectal cancer. Cancer Invest 2005; 23: 338-351.
4. Locker GY, Hamilton S, Harris J et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol 2006; 24: 5313-5327.
5. Ailawadhi S, Sunga A, Rajput A et al. Chemotherapy-induced carcinoembryonic antigen surge in patients with metastatic colorectal cancer. Oncology 2006; 70: 49-53.
6. Sorbye H, Dahl O. Transient CEA increase at start of oxaliplatin combination therapy for metastatic colorectal cancer. Acta Oncol 2004; 43: 495-498.
7. Therasse P, Arbuck SG, Eisenhauer EA et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000; 92: 205-216.
8. Folprecht G, Seymour MT, Saltz L et al. Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials. J Clin Oncol 2008; 26: 1443-1451.
9. Kohne CH, Cunningham D, Di CF et al. Clinical determinants of survival in patients with 5-fluorouracil-based treatment for metastatic colorectal cancer: results of a multivariate analysis of 3825 patients. Ann Oncol 2002; 13: 308-317.
10. Cunningham D, Sirohi B, Pluzanska A et al. Two different first-line 5-fluorouracil regimens with or without oxaliplatin in patients with metastatic colorectal cancer. Ann Oncol 2009; 20: 244-250.
11. Koopman M, Antonini NF, Douma J et al. Sequential versus combination chemotherapy with capecitabine, irinotecan, and oxaliplatin in advanced colorectal cancer (CAIRO): a phase III randomised controlled trial. Lancet 2007; 370: 135-142.
12. Seymour MT, Maughan TS, Ledermann JA et al. Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial. Lancet 2007; 370: 143-152.
13. Thompson JA, Grunert F, Zimmermann W. Carcinoembryonic antigen gene family: molecular biology and clinical perspectives. J Clin Lab Anal 1991; 5: 344-366.
14. Hostetter RB, Augustus LB, Mankarious R et al. Carcinoembryonic antigen as a selective enhancer of colorectal cancer metastasis. J Natl Cancer Inst 1990; 82: 380-385.
15. Modrak DE, Gold DV, Goldenberg DM et al. Colonic tumor CEA, CSAp and MUC1 expression following radioimmunotherapy or chemotherapy. Tumour Biol 2003; 24: 32-39.
16. Ohtsukasa S, Okabe S, Yamashita H et al. Increased expression of CEA and MHC class I in colorectal cancer cell lines exposed to chemotherapy drugs. J Cancer Res Clin Oncol 2003; 129: 719-726.
17. Aquino A, Prete SP, Greiner JW et al. Effect of the combined treatment with 5-fluorouracil, gamma-interferon or folinic acid on carcinoembryonic antigen expression in colon cancer cells. Clin Cancer Res 1998; 4: 2473-2481.
18. Prete SP, Turriziani M, Massara MC et al. Combined effects of 5-fluorouracil, folinic acid and oxaliplatin on the expression of carcinoembryonic antigen in human colon cancer cells: pharmacological basis to develop an active antitumor immunochemotherapy. J Exp Clin Cancer Res 2008; 27: 5.